COMMUNIQUÉS West-GlobeNewswire

-
STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal
07/06/2024 -
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/06/2024 -
Nusano Names D. Scott Holbrook as Chairman of its Board
07/06/2024 -
GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Extension of Agreement with PeaceHealth Sacred Heart Medical Center at RiverBend
07/06/2024 -
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
07/06/2024 -
Epic Bio to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress
07/06/2024 -
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
07/06/2024 -
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/06/2024 -
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
07/06/2024 -
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
07/06/2024 -
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
07/06/2024 -
RadNet, Inc. to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
07/06/2024 -
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07/06/2024 -
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07/06/2024 -
EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia
07/06/2024 -
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
07/06/2024 -
Rapport Therapeutics Announces Pricing of Initial Public Offering
07/06/2024 -
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
07/06/2024 -
UPDATED: Public Hearings on Protecting and Improving Local Hospitals: Community members invited to give input
06/06/2024
Pages